Panelists discuss how RWE informs treatment and safety decisions for special populations such as patients with ECOG PS 2 with ...
Panelists examine the value of patient-reported outcomes (PROs) in helping guide therapy selection for later-line metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback